Trial Profile

Phase II proof of concept study of baricitinib in individuals who are considered at risk of developing inflammatory arthritis: ExIST

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 16 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Baricitinib (Primary) ; Anti-inflammatories
Indications Arthritis; Inflammation
Focus Proof of concept; Therapeutic Use
Acronyms ExIST

Most Recent Events

12 Aug 2024 Recruitment completion is expected on 09/12/2025, according to ISRCTN Clinical Trials Registry record.
12 Aug 2024 Planned End Date changed from 26 Jun 2026 to 12 Oct 2027.
07 Dec 2022 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com